He hops off a helicopter, whips off his shades and makes a dash through the grounds towards his home to give his mother a surprise, but there she is, waiting at the door with a pooja thali' in her hand. That admittedly cheesy scene between Shah Rukh Khan and Jaya Bachchan from the blockbuster Hindi film Kabhi Khushi Kabhi Gham was playing in Sonali Puri's mind when she was on a Mumbai-Jammu flight to give her mother a surprise last month. Her mother was at the door just as she had imagined but instead of a thali' was a hand sanitiser! Good hygiene is a blessing in times of coronavirus, my mother told me, laughed the 37-year-old. That was in mid-March, a few days before the coronavirus forced lockdown began on March 25. And home in Jammu is where Puri still is, the short vacation turning into extended mother-daughter downtime, both recalibrating their equations as they spend focused time with each other after years. This Mother's Day, the first time in years perhaps that Puri has been .

TVS Eurogrip has announced a new feature of an e-ordering facility in its retailer app 'TVS Eurogrip Bandhan', which can be downloaded on both Android and iOS platforms. This new feature in the app will provide a comprehensive e-commerce experience with features that help place and track orders.

Work on vaccine development has been initiated between the two partners.

ICMR partners with BBIL for developing indigenous coronavirus vaccine

Smithsonian astronomers have just discovered a rare example of a galaxy that appears to have a pair of giant black holes. Now they are trying to determine if those black holes are partners tied together by gravity, or if one of the two has been kicked out in a cosmic breakup.

The post Double Black-Hole Mystery: Dance Partners or Breakup Survivors? appeared first on Smithsonian Insider.

Although the La Loma tree frog, Hyloscirtus colymba, is notoriously difficult to care for in captivity, the Panama Amphibian Rescue and Conservation Project is the first to successfully breed this species.

The post National Zoo and partners first to breed critically endangered tree frog appeared first on Smithsonian Insider.

Scientists and educators from the Smithsonian Conservation Biology Institute and George Mason University broke ground June 29 on a green-design conservation complex that embodies the concept of the living classroom.

The post Smithsonian Conservation Biology Institute and George Mason University expand partnership appeared first on Smithsonian Insider.

A new study by astrophysicists at the University of Utah and the Smithsonian Astrophysical Observatory in Cambridge, Mass., has found a new explanation for the growth of supermassive black holes: they repeatedly capture and swallow single stars from pairs of stars that get too close.

The post Steady diet of binary star partners makes black holes grow “supermassive” appeared first on Smithsonian Insider.

Partners in the Sky: Aviation and Aerospace Industry Leaders Join The Smithsonian In Worldwide Conservation Efforts Partnership Will Revolutionize Animal Tracking

The post Partners in the Sky appeared first on Smithsonian Insider.

The Smithsonian Conservation Biology Institute and the SVF Foundation have launched a new collaboration to strengthen rare and endangered livestock breed conservation through the preservation […]

The post Smithsonian & SVF launch rare-breed livestock conservation partnership appeared first on Smithsonian Insider.

After decades of attempts, Smithsonian Conservation Biology Institute (SCBI) scientists and researchers at Cornell University have become the first to successfully use in vitro fertilization […]

The post Smithsonian-Cornell Partnership produces First Domestic Puppies by In Vitro Fertilization appeared first on Smithsonian Insider.

The HSBC Climate Partnership (HCP) is a five-year partnership (2007-2011) between HSBC, The Smithsonian, The Climate Group, Earthwatch Institute and WWF to inspire action on climate change.
Working with these partners and engaging its employees around the world, HSBC hopes to tackle climate change impacts for people, forests, water, and cities. The HCP research of the Smithsonian's Center for Tropical Forest Science (CTFS) focuses on:
• Understanding the role of forests in the global carbon cycle
• Comparing temperate and tropical forests by establishing new plots in the temperate zone
• Quantifying the environmental services provided by tropical forests

The post The HSBC Climate Partnership is a five-year partnership to inspire action on climate change appeared first on Smithsonian Insider.

Unlocking the mysteries of animal migration through precise, near real-time tracking can solve major conservation challenges and transform wildlife science worldwide. For the past year, […]

The post Partners in the Sky appeared first on Smithsonian Insider.

The Smithsonian’s National Museum of Natural History announced today that scientists with the museum’s Global Genome Initiative will attempt to capture the genomic diversity of half the […]

The post Smithsonian and Partners To Preserve Earth’s Genomic Plant Diversity appeared first on Smithsonian Insider.

(The Paypers) AML data and tech company Vital4 has revealed its partnership with UK-based

(The Paypers) Acuant, a global identity verification solutions provider, has teamed up with

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

Netherlands-based payments platform

Canada-based digital transaction processor Carta Worldwide teamed with

As the recent spread of West Nile virus and the anthrax scare of 2001 dramatically illustrate, America faces a variety of new health challenges in the 21st century, along with a number of persistent problems, such as racial disparities in health status and care delivery.

The U.S. DRIVE Partnership – a government-industry partnership that fosters the development of precompetitive and innovative technologies for clean and efficient light-duty vehicles – has made significant progress in many technical areas including advanced combustion technologies, durability and cost of hydrogen fuel cells, and electric drive systems such as motors, power electronics, and batteries, says a new report by the National Academies of Sciences, Engineering, and Medicine.

The U.S. National Academies of Sciences, Engineering, and Medicine are now serving as the host for the InterAcademy Partnership for Research (IAP-R) secretariat.

In recognition of the need for a national coordinated and collective response to the epidemic of opioid addiction in the U.S., the National Academy of Medicine (NAM), in partnership with the Aspen Institute, launched a public-private partnership made up of more than 35 organizations representing federal, state, and local governments, health systems, associations and provider groups, health education and accrediting institutions, pharmacies, payers, industry, nonprofits, and academia.

Renewed interest in exploration of the moon has the potential to benefit lunar science greatly and could evolve into a program facilitated by partnerships between commercial companies and NASA’s Science Mission Directorate (SMD), say companion reports by the National Academies of Sciences, Engineering, and Medicine.

UATP has partnered the payment technology company

Coda Payments and Riot Games have announced that players...

Sephora has partnered with Klarna to offer its...

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

South-Africa based PSP Thumbzup and cloud service distributor

With the latest deal, Jio Platforms is set to net a combined Rs 60,596 crore for the unit of Reliance Industries which comprises mainly its telecom business under Reliance Jio Infocomm

Onymos has transformed the art of mobile apps development, where open standards HTML, JavaScript and CSS technologies are made use of, which in turn, cuts down the development time from months to days.

A new study provides a 'snapshot' of the environmental skills programmes available across different industries in EU Member States. The study highlights the importance of partnerships – between public and private sector, and between different industry sectors – in ensuring the European workforce acquires the necessary skills to make the transition to a low-carbon, sustainable economy.

A new report highlights the connections between climate change risks and opportunities, sustainable development and climate change adaptation, to provide a useful guidance for business and policymakers in creating a green economy. It suggests that businesses are an essential partner in preparing for and responding to the impacts of climate change.

Throughout Europe and beyond, the delivery of flood risk management (FRM) is increasingly being seen as the shared responsibility of governmental actors and citizens. However, a new study, which explored the viewpoints of stakeholders in a flood-prone part of Belgium, found that citizens see FRM mainly as the government’s responsibility.